Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareho... ( Other results In 2008 net ...)

Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value

Date:2/26/2009

Other results

In 2008, net financial income amounted to EUR5.5 million compared to EUR5.2 million in 2007 and represents mainly the returns on the financial investments of the Group's cash, cash equivalents and financial instruments.

The income tax expense incurred by NicOx in 2008 relates to its subsidiaries and amounted to EUR0.1 million, identical to 2007.

Net result

The net loss reached EUR73.9 million in 2008 compared to EUR32.1 million in 2007. As indicated above, this very significant increase in net loss in 2008 is due to the strong increase of research and development expenses associated with naproxcinod and from the considerable decrease in the revenues recognized in 2008.

Balance sheet items

The indebtedness incurred by NicOx is mainly short-term operating debt. On December 31, 2008, the Company's current liabilities amounted to EUR21.2 million, including EUR16.2 million in accounts payable to suppliers and external collaborators, EUR2.1 million in accrued compensation for employees, EUR1.5 million in taxes payable, EUR1.1 million in deferred revenues due to payments received under collaboration agreements and EUR0.3 million for other liabilities.

In 2008, NicOx granted to Archimica a loan of EUR6.0 million as part of the financial terms of the manufacturing and supply agreement with this company. Following the termination of the agreement in November 2008, EUR5.0 million out of the EUR6.0 million loan were forgiven in accordance with the terms of the agreement and Archimica remains liable to NicOx, as of December 31, 2008, of an amount of EUR0.9 million with regards to this loan. Considering there is a risk for the recovery of this sum, the Company has decided to depreciate partially this asset and has booked as of December 31, 2008 a contingency provision for an amount of EUR0.5 million.

On December 31, 2008, the Co
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results

Post Your Comments:

(Date:5/25/2013)... Czech Republic (PRWEB) May 25, 2013 ... nanoscale optical manipulation have been recognized with presentation of ... (ICO). The presentations were made 16 April during the ... SPIE, the international society for optics and photonics , ... Jan Perina of Palacký University was presented with the ...

(Date:5/25/2013)... Dennis R. HIll M.D. Radiation Oncologist at the Alta Bates ... has been a promotion of the idea that a newer ... low dose rate, brachytherapy for prostate cancer. The claim is ... half life, and gives a higher biologically effective dose to ... higher average energy than the other commonly used prostate cancer permanent ...

(Date:5/24/2013)... 24, 2013 Dr. Ingrid Warmuth and Anamaria ... NJ, are proud to announce an Open House at their ... on Saturday, June 8th from 10 AM to 2 PM. ... MHS, PA-C and staff will be on hand to talk ... aesthetic treatments, and provide complimentary cosmetic consultations. There will also ...

(Date:5/24/2013)... (PRWEB) May 24, 2013 In ... and industry suppliers will present technologies with applications ... the annual SPIE Optics and Photonics ... by SPIE, the international society for optics ... international, multidisciplinary optical sciences and technology meeting in ...

Breaking Biology Technology:ICO Honors Three with Awards during SPIE Optics and Optoelectronics 2 ICO Honors Three with Awards during SPIE Optics and Optoelectronics 3 Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 2 Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 3 See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2 See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3 See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4

[0] ICO Honors Three with Awards during SPIE Optics and Optoelectronics [0] Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same [0] Dr. Ingrid Warmuth Skin Care Center Announces An Open House At Their Swedesboro Location [0] See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics

... Same Prior Year Period, DUBLIN, Calif., April 28 ... results for the first quarter ended,March 31, 2008., ... million, compared,with $4.4 million for the same prior year ... $8.1 million in royalty revenue, compared,with $3.8 million for ...

... Year, Based on Positive Operating Results and One-Time ... of $122.6 Million, Product Sales Rise 16% to All-Time High of $101.5 Million ... Revenues of ... $455 Million -, SAN DIEGO, April 28 Gen-Probe Incorporated,(Nasdaq: GPRO ) ...

... 28 Simcere,Pharmaceutical Group (NYSE: SCR ), ... and manufacturer of the patented,anti-cancer biotech product Endu ... 3rd Annual Healthcare Trip, to be held May,6-10 ... Weihai., Simcere senior management will give a ...

SuperGen Reports 2008 First Quarter Financial Results Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip

(Date:5/22/2013)... a novel technique that can detect molecular variants in ... one of the most important, though time-consuming, processes in ... in Nature , post-doctoral researcher David Patterson, Professor ... the Center for Free-Electron Laser Science (CFEL) in Hamburg, ... fields to identify molecular variants apart, and to determine ...

(Date:5/22/2013)... human health effects from disposal of millions of ... to recommend stronger government policies to encourage recovery, ... That,s the conclusion of a new paper in ... . , Oladele A. Ogunseitan and colleagues point ... powering everything from smart phones to components in ...

(Date:5/22/2013)... 2013 Early screening for prostate cancer could become ... for women, thanks to UC Irvine research published today ... . , After more than a decade of work, ... identify clinically usable markers for prostate cancer in urine, ... with greater accuracy and at dramatically lower cost. The ...

Breaking Biology News(10 mins):Detecting mirror molecules 2 Detecting mirror molecules 3 UCI chemists devise inexpensive, accurate way to detect prostate cancer 2 UCI chemists devise inexpensive, accurate way to detect prostate cancer 3

[0] Detecting mirror molecules [0] More emphasis needed on recycling and reuse of Li-ion batteries [0] UCI chemists devise inexpensive, accurate way to detect prostate cancer

... Safes, a new,report by market research publisher SBI, forecasts that ... 2008 and beyond, topping $308,million by 2011. At $221 million ... safes market. In terms of units, personal safes account,for an ... year in,the U.S., 60% of which are sold in the ...

... Harbor, NY Cancer patients usually ask what can be ... to other organs. In many cases, they learn, little can ... at Cold Spring Harbor Laboratory (CSHL) of a type of ... into large, aggressive metastases the kind that kill cancer ...

... accepted belief that substantial ice sheets could not have ... study by researchers at Scripps Institution of Oceanography at ... ice cap, about half the size of the modern ... during a period of intense global warming. This study ...

Cached Biology News:Personal Safes Market to Top $308 Million by 2011 2 CSHL scientists identify cells that promote formation of lethal lung metastases 2 A warming climate can support glacial ice 2 A warming climate can support glacial ice 3

Personal Safes Market to Top $308 Million by 2011 CSHL scientists identify cells that promote formation of lethal lung metastases A warming climate can support glacial ice

...

Anti-Human Factor XIII HRPO (Polyclonal) (sheep IgG)...

Recognizes the 41 and 43 kDa G-proteins present in liver plasma membranes and Gq/11alpha expressed in the Sf9 insect cell expression system. Negative for recombinant G(I)alpha subtypes....

Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....

Biology Products:

Silencer siRNA Starter Kit from Ambion Sheep Anti-Human Factor XIII Antibody, Horseradish Peroxidase Conjugated from CEDARLANE Laboratories Limited Anti-G Protein Gq / 11a Subunit, Internal Sequence, a.a. 115-133 Polyclonal Antibody, Unconjugated from CHEMICON Rabbit Anti-Burkholderia pseudomallei Flagellin Polyclonal Antibody, Unconjugated from Abcam